Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | PPARA | Q07869 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849149 | 0.83 | KDM4E (0.44) | PPARGPPARASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2080149 | 0.82 | MEN1 (0.57) | SMN1; SMN2ALDH1A1KDM4EHSD17B10TP53 | |
| SCHEMBL4844166 | 0.82 | PPARG (0.46) | PPARGPPARASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2078397 | 0.81 | KDM4E (0.52) | PPARGSMN1; SMN2ALDH1A1KDM4EHTT | |
| SCHEMBL4853675 | 0.77 | KDR (0.46) | PPARGPPARASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4852206 | 0.76 | ALDH1A1 (0.52) | PPARGPPARASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL12918698 | 0.74 | MAPK14 (0.51) | SMN1; SMN2ALDH1A1KDM4EHTTESR2 | |
| SCHEMBL12163682 | 0.74 | POLB (0.55) | ALDH1A1KDM4EHTTHSD17B10THRB | |
| SCHEMBL70184 | 0.73 | KDM4E (0.47) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL1436823 | 0.72 | PPARA (0.43) | PPARGPPARAALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | PPARG 536/4885PPARA 519/4885SMN1; SMN2 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.